SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has reignited discussion of Starknets privacy and Bitcoin-DeFi push, including shielded assets and strkBTC, alongside its STARK-based, post-quantum security narrative. Traders are bullish on the technology and momentum, while some remain wary of token unlocks and the tokens weak longer-term price action.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing attention for sharp rallies and rebounds, with traders citing CME futures access and an anticipated CashVM/Layla upgrade as bullish themes; others remain skeptical about BCHs utility and warn that the moves may reverse.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 analyses of Verastems avutometinibdefactinib combination are drawing attention for reported activity in KRAS-wild-type ovarian cancer and comparisons with conventional care. Traders debate whether the data could broaden the treatment opportunity, while some are frustrated by the muted share reaction and are also watching for VS-7375 clinical data.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins shares are under pressure after a court denied its request to temporarily block Unitys Ad Quality SDK, leaving the disputed tool in operation while the legal fight continues; traders also cite cautious analyst commentary about growth and Pixel adoption. The selloff has fueled debate between bears concerned about competitive pressure and bulls who view the decline as overdone given the companys profitability and growth.

Pump.fun

PUMP is drawing attention for a sharp rebound, with traders pointing to buybacks, Pump.funs revenue and trading activity, and renewed interest in Solana memecoins as bullish context. The discussion remains divided: some see the move continuing, while others call it a speculative pump or warn of another selloff.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on DefenCaths commercial outlook after CorMedix secured a DaVita agreement, especially whether adoption can offset lower post-TDAPA reimbursement. Traders debate the prospects for CMS or Medicare Advantage reimbursement and how DefenCaths real-world evidence compares with ClearGuard; REZZAYOs positive Phase 3 results and anticipated supplemental filing are also drawing attention.

JinkoSolar Holding Co., Ltd. engages in the manufacture of solar modules. It distributes solar products and sells its solutions and services to a diversified international utility, commercial and residential customers. The company was founded by Xian De Li, Kang Ping Chen, and Xian Hua Li in June 2006 and is headquartered in Shangrao, China.

JinkoSolar Holding Co. Ltd - ADR

JinkoSolar Holding Co LTD

JinkoSolars steep decline and weak latest results dominate discussion, with traders citing quarterly earnings and revenue misses and a lower shipment outlook amid solar-industry oversupply and margin pressure. Bulls argue the shares look undervalued and point to the dividend, while bears focus on losses and squeezed margins; claims of short-driven manipulation remain speculation.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgos OpenAI-linked autonomous-lab work is drawing attention after reports that a GPT-5-driven lab cut cell-free protein-synthesis costs by about 40%, fueling optimism about AI-enabled biology and the companys lab-automation pivot. Skeptics counter that technical progress and high-profile collaborations still need to translate into meaningful commercial revenue.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Discussion is focused on reports that Subsquid CEO Wanja Oberhof was charged with fraud tied to a former venture; the allegations do not concern SQD, but traders are debating whether the governance connection could affect Subsquid or Rezolves retained contractual rights. Some see it as unrelated to SQD, while others remain concerned; bullish posts also point to SQDs blockchain-data infrastructure and enterprise-adoption potential.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Pharvariss positive Phase 3 results for its oral HAE drug have raised concerns that it could compete with BioCrysts Orladeyo and complicate the outlook for navenibart. Traders disagree on the impact: some see a long runway before the rival drug reaches market and limited switching among established patients, while others fear future market-share losses and weaker growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


hm88bid

HM88 bid